Groundbreaking kidney drug enters human testing phase
NCT ID NCT07267026
Summary
This is the first human study of an experimental oral medication called SK-09, which is being developed for two serious kidney diseases (FSGS and MCD). The trial will test the safety, side effects, and how the drug moves through the body in 72 healthy adult volunteers. Researchers will give participants either the drug or a placebo (inactive substance) in increasing single and multiple doses to determine if it's safe enough for further testing in patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FSGS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Q-Pharm Pty Ltd.
RECRUITINGHerston, Queensland, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.